Calgene's Flavr Savr 'PG Gene' Patent US4801540, Read Back 38 Years After the World's First Commercial GMO Food
About these "memos": Memos in this series record a candidate at the stage where the primary-source URL has been verified. This memo includes Claim 1, inventors, dates, and assignee from Google Patents, but the full specification (SEQ ID NOs, transformation protocol, field-trial data, drawings) has not been read end-to-end. Confirmed facts only; inferences are flagged as such.
Why dig here
The Flavr Savr tomato received US FDA clearance in May 1994 and became the world's first commercial GMO food. The starting point is US4801540A, filed by Calgene LLC of Davis, California in 1986: an antisense suppression of tomato polygalacturonase (PG) intended to slow softening of ripe fruit. This memo treats the foundational patent's Claim 1 and antisense-suppression drafting, which is also the entry point to the late-1990s consolidation under Monsanto and the GMO regulatory debates of that decade.
Patent essentials
- Patent: US4801540A
- Title: PG gene and its use in plants
- Priority: 1986-10-17
- Filed: 1987-01-02
- Granted: 1989-01-31
- Inventors: William R. Hiatt; Raymond E. Sheehy; Christine K. Shewmaker; Jean C. Kridl; Vic Knauf (five co-inventors)
- Original assignee: Calgene LLC (Davis, California)
- Current assignee: Monsanto Co. (via the 1997 acquisition of Calgene)
- Primary source: Google Patents (URL confirmed; Claim 1 retrieved)
Claim 1 (verbatim)
A DNA sequence which is uninterrupted, encodes tomato polygalacturonase (PG) and is flanked by at least one non-wild type DNA sequence 5' to or 3' to said polygalacturonase encoding sequence.
The claim covers an "uninterrupted" sequence (cDNA-format, intron-free) encoding tomato PG, with at least one non-wild-type flanking sequence — i.e., a constructed cDNA, not the natural genomic context. The specification frames antisense expression of this construct in tomato: the antisense RNA hybridizes with endogenous PG mRNA and suppresses translation (the description excerpt notes "anti-sense orientation allows for inhibiting the expression of PG").
Antisense suppression and the link to Flavr Savr
| Element | What's confirmed in the primary source |
|---|---|
| Role of PG | Hydrolyzes pectin during ripening, softening fruit |
| Antisense design | RNA complementary to PG mRNA suppresses translation |
| Tomato cultivar | 'CaliGrande' is identified as the mRNA source |
| Intended effect | Pectin hydrolysis is slowed, allowing on-vine ripening before harvest without softening in distribution |
| Product name | "Flavr Savr" is not stated in the patent itself; the brand was assigned at commercialization |
Commercialization and acquisition timeline (primary vs. secondary)
| Year | Event | Source type |
|---|---|---|
| 1986-10-17 | US4801540A priority filing (Calgene) | Primary (Google Patents) |
| 1989-01-31 | US4801540A grant | Primary (Google Patents) |
| 1992 | FDA articulates GMO-food policy ("substantial equivalence") | Secondary (FDA public site) |
| 1994-05-21 | FDA clears Flavr Savr (world's first commercial GMO food) | Secondary (Wikipedia / FDA press release aggregation) |
| 1994-05-24 | Calgene begins retail sales (California, Illinois) | Secondary (Wikipedia / news aggregation) |
| 1996–1997 | Production ends — distribution costs, post-harvest handling, lukewarm consumer reception | Secondary (Wikipedia / Calgene corporate history) |
| 1997 | Monsanto fully acquires Calgene; patent transfers | Secondary (Wikipedia / Monsanto corporate history) |
The commercialization timeline is secondary; original Calgene board minutes and FDA filing dossiers are not retrieved here.
Modern resonance
| US4801540A (1986) | Modern (2026) | Verdict |
|---|---|---|
| Antisense-RNA suppression of gene expression | RNAi (Fire & Mello 1998 Nobel) and CRISPRi (CRISPR interference) | Metaphor (problem-framing inherited; mechanism differs — antisense uses single-stranded RNA, RNAi uses double-stranded RNA, CRISPRi uses dCas9) |
| Suppress PG → fruit shelf-life | Modern non-browning apple (Arctic Apple, PPO silencing, on sale 2017) | Similar (same design strategy; different crop / different enzyme) |
| Calgene → Monsanto consolidation | Monsanto → Bayer (2018) — final ownership in the Bayer agribusiness portfolio | Similar (the consolidation arc of GMO-seed IP) |
| World's first commercial GMO food fails commercially | Modern GMO-food consumer reception (US widely adopted, EU restrictive, Japan limited approvals) | Similar (the regulatory and reception split since the late 1990s reflects the Flavr Savr experience) |
| 1986 GM-tomato patent | 2020s CRISPR tomato (Sicilian Rouge High GABA, Sanatech Seed, on sale Japan 2021) | Metaphor (cross-era genealogy; genome editing and transgenic recombination sit in different regulatory categories) |
Pitfalls
Pitfall 1: scope of "world's first" Flavr Savr (1994) was "the first FDA-cleared transgenic food sold to consumers in retail." Research-grade GMOs predate it (Monsanto petunia 1983, Calgene tobacco 1985). Limit "world's first" to commercial retail.
Pitfall 2: don't oversimplify the failure Popular accounts attribute the failure mainly to "consumer rejection," but Calgene's internal experience was a compound of (a) thin skin / transit damage and weak distribution infrastructure, (b) high labor cost of vine-ripe harvest, (c) inability to justify the price premium, (d) difficulty differentiating from local in-season tomatoes. This memo does not adjudicate the relative weights.
Pitfall 3: composition vs. use claim The claimed subject matter is a DNA sequence + non-wild-type flanking — a construct claim, not the natural tomato PG genomic sequence. After the 2013 US Supreme Court Myriad Genetics BRCA1/2 decision (naturally occurring DNA sequences are not patent-eligible), eligibility around natural genomic sequences tightened, but a constructed sequence still survives the test, so this patent's validity framework is unaffected by Myriad.
Open items
- Full specification, including SEQ ID NOs, transformation protocol, field-trial data, and figures
- Forward-citation count and links to subsequent GMO patents
- License value and IP appraisal at the 1997 Calgene acquisition
- Verbatim text of the FDA's May 21 1994 clearance
- Detailed succession of ownership of this patent post-Bayer 2018
- Comparison with contemporaneous third-party plant-genetic-engineering patents (Agrobacterium tumefaciens transformation, etc.)
Next moves
When this gets upgraded from memo to note, retrieve (a) the full specification and SEQ ID NO structural analysis, (b) the FDA 1994 clearance document, (c) Calgene's SEC filings around the 1997 acquisition, (d) the post-2018 Bayer succession trail, and (e) contemporaneous competitor GMO filings — to map the first generation of commercial GMO IP. Day 14 ep54's cisplatin formulation patent US4310515A and its "lock down a public-domain compound on a different layer" pattern is a useful comparison frame.
References:
- Original patent: US4801540 on Google Patents
- Food & Health Patents Note #4: Aspartame US3492131A
- Food & Health Patents Memo #4: Teflon US2230654A
- Food & Health Patents Memo #5: MSG commercial patent US1015891A
- Wikipedia: Flavr Savr (https://en.wikipedia.org/wiki/Flavr_Savr)
- Wikipedia: Calgene (https://en.wikipedia.org/wiki/Calgene)